Pharmabiz2d
DFE Pharma expands its C2F Center of Excellence in Hyderabad to advance the development of critical respiratory treatments
DFE Pharma, a global leader in pharmaceutical and biopharmaceutical excipient solutions, has expanded the capabilities of its Closer to the Formulator (C2F) Center of Excellence located in Genome ...
Pharmabiz2d
Illumina launches pilot proteomics programme with UK Biobank and biopharma collaborators to analyze 50,000 samples
Illumina launches pilot proteomics programme with UK Biobank and biopharma collaborators to analyze 50,000 samples: San Diego Tuesday, January 14, 2025, 13:00 Hrs [IST] Illumina, ...
Pharmabiz2d
Telix to buy next-generation therapeutic assets and innovative biologics technology platform from ImaginAb
Telix, a commercial-stage biopharmaceutical company, announces it has entered into an asset purchase agreement with antibody engineering company ImaginAb, Inc. (ImaginAb) to acquire a pipeline of next ...
Pharmabiz2d
Telix enters agreement with Curium Pharma for transfer of marketing and distribution rights for Scintimun
Telix, a commercial-stage biopharmaceutical company focused on the development and commercialisation of therapeutic and diagnostic (‘theranostic’) radiopharmaceuticals, announces that it has entered ...
Pharmabiz6d
FPME demands policy reforms to address critical issues hampering export ecosystem
The Federation of Pharmaceutical and Allied Products Merchant Exporters (FPME) has urged the authorities to address critical issues hampering India's pharmaceutical export ecosystem, highlighting the ...
Pharmabiz6d
AIPPSPA urges Kerala DCA to carry out separate inspections at discount pharmacies to ensure quality of drugs
Expressing concerns over the quality of medicines sold through discount pharmacies in Kerala, the state president of the All India Public and Private Sector Pharmacists Association (AIPPSPA), ...
Pharmabiz5d
NPPA recalculates ceiling price of azithromycin 250 mg following review order
The National Pharmaceutical Pricing Authority (NPPA) has released the revised calculation sheet for the ceiling price of azithromycin 250 mg tablet following a review order from the Department of ...
Pharmabiz5d
CAGE Bio begins phase 2b clinical trial for CGB-500, a breakthrough topical JAK inhibitor for moderate to severe atopic dermatitis
CAGE Bio, Inc., a clinical-stage biotechnology company advancing innovative therapies for high incidence immuno-dermatological disorders, announced the initiation of a phase 2b dose-ranging trial for ...
Pharmabiz5d
Boehringer Ingelheim broadens oncology portfolio with license for Synaffix’s ADC technology
Boehringer Ingelheim and Synaffix B.V. (Synaffix), a Lonza company focused on commercializing its clinical-stage platform technology for the development of best-in-class antibody-drug conjugates (ADCs ...
Pharmabiz7d
Parliamentary panel asks PMBI to take steps to ensure quality of drugs sold through JAKs
The Parliamentary panel that reviewed the budget allocation for the Department of Pharmaceuticals (DoP) and related matters has sought the Pharmaceuticals & Medical Devices Bureau of India (PMBI), the ...
Pharmabiz6d
WHO prequalifies SD Biosensor’s STANDARD G6PD System to support safer administration of P. vivax malaria treatments
The World Health Organization (WHO) prequalified the first diagnostic test for glucose-6-phosphate dehydrogenase (G6PD) deficiency which can help to safely deliver WHO-recommended treatments to ...
Pharmabiz6d
STADA has retained Andreas Fibig as independent chairman of its future board of directors
At the turn of the year, STADA's owners Cinven and Bain Capital are setting the course for the future. No decision has yet been taken; various options are under consideration, including an initial ...